Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.73 |
| ▸ | EGFR | P00533 | 9/20 | 0.73 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22400925 | 0.88 | EGFR (0.75) | BTKEGFRUSP30SYKRIPK2 | |
| SCHEMBL22405025 | 0.86 | BTK (0.76) | BTKEGFRUSP30SYKRIPK2 | |
| SCHEMBL30091819 | 0.84 | EGFR (1.00) | BTKEGFR | |
| SCHEMBL22404957 | 0.84 | EGFR (1.00) | BTKEGFR | |
| SCHEMBL30091792 | 0.84 | EGFR (0.73) | BTKEGFRRIPK2ALDH1A1NPC1 | |
| SCHEMBL22400981 | 0.84 | EGFR (0.73) | BTKEGFRRIPK2ALDH1A1NPC1 | |
| SCHEMBL28466941 | 0.84 | EGFR (0.76) | BTKEGFRUSP30RIPK2 | |
| SCHEMBL30091817 | 0.84 | EGFR (0.76) | BTKEGFRUSP30RIPK2 | |
| SCHEMBL22404973 | 0.82 | ALDH1A1 (0.53) | BTKEGFRUSP30GPR119SYK | |
| SCHEMBL4929565 | 0.82 | ALDH1A1 (0.56) | BTKEGFRUSP30GPR119RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542249-B2 | BTK inhibitor compounds | ELI LILLY AND COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542249-B2 | BTK inhibitor compounds | ELI LILLY AND COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | BTK, SYK, LCK | BTK 1/4885EGFR 403/4885USP30 1692/4885 |
| US-11542249-B2 | BTK inhibitor compounds | BTK, SYK, LCK | BTK 1/4885EGFR 380/4885USP30 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.